{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:04Z","timestamp":1789685524423,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40744-025-00801-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:18:10Z","timestamp":1761211090000},"page":"1159-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness and Satisfaction with Risankizumab for the Treatment of Psoriatic Arthritis in Biologic-Na\u00efve Patients: A Population Survey in the United States and Europe"],"prefix":"10.1007","volume":"12","author":[{"given":"Jessica A.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Saffore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Biljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Truman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ostor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"1","key":"801_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis Nat Rev Dis Primers. 2021;7(1):59. https:\/\/doi.org\/10.1038\/s41572-021-00293-y.","journal-title":"Psoriatic arthritis Nat Rev Dis Primers"},{"issue":"1","key":"801_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.027.","journal-title":"J Am Acad Dermatol"},{"key":"801_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae198","author":"S Lembke","year":"2024","unstructured":"Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis. Rheumatology (Oxford). 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae198.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"801_CR4","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1097\/RHU.0000000000001575","volume":"27","author":"JA Walsh","year":"2021","unstructured":"Walsh JA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. J Clin Rheumatol. 2021;27(8):e547\u201360. https:\/\/doi.org\/10.1097\/RHU.0000000000001575.","journal-title":"J Clin Rheumatol"},{"key":"801_CR5","doi-asserted-by":"publisher","unstructured":"Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8. https:\/\/doi.org\/10.12688\/f1000research.19144.1.","DOI":"10.12688\/f1000research.19144.1"},{"key":"801_CR6","doi-asserted-by":"publisher","unstructured":"Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.039.","DOI":"10.1016\/j.jaad.2008.02.039"},{"issue":"6","key":"801_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40257-018-0377-2","volume":"19","author":"J Bagel","year":"2018","unstructured":"Bagel J, Schwartzman S. Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol. 2018;19(6):839\u201352. https:\/\/doi.org\/10.1007\/s40257-018-0377-2.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"801_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona psoriatic arthritis\/spondyloarthritis registry. Arthritis Care Res (Hoboken). 2017;69(11):1692\u20139. https:\/\/doi.org\/10.1002\/acr.23249.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"801_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaad.2024.02.026","volume":"91","author":"L Nymand","year":"2024","unstructured":"Nymand L, Kristensen LE, Thomsen SF, Thyssen JP, Egeberg A. Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: a cross sectional study. J Am Acad Dermatol. 2024;91(1):57\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2024.02.026.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"801_CR10","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","volume":"60","author":"C Ballegaard","year":"2021","unstructured":"Ballegaard C, Skougaard M, Guldberg-Moller J, et al. Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study. Rheumatology (Oxford). 2021;60(7):3289\u2013300. https:\/\/doi.org\/10.1093\/rheumatology\/keaa780.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"801_CR11","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/art.41741","volume":"73","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Crowson CS, Bekele D, et al. The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol. 2021;73(10):1878\u201385. https:\/\/doi.org\/10.1002\/art.41741.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"801_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10(3):589\u201399. https:\/\/doi.org\/10.1007\/s40744-023-00535-3.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"801_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s40744-023-00602-9","volume":"10","author":"N Frede","year":"2023","unstructured":"Frede N, Hiestand S, Schauer F, et al. Psoriasis and psoriatic arthritis have a major impact on quality of life and depressive symptoms: a cross-sectional study of 300 patients. Rheumatol Ther. 2023;10(6):1655\u201368. https:\/\/doi.org\/10.1007\/s40744-023-00602-9.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"801_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K. Risankizumab: mechanism of action, clinical and translational science. Clin Transl Sci. 2024;17(1):e13706. https:\/\/doi.org\/10.1111\/cts.13706.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"801_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319. https:\/\/doi.org\/10.1136\/ard-2024-225531.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"801_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379. https:\/\/doi.org\/10.1038\/s41584-022-00798-0.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"801_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-024-00654-5","volume":"11","author":"LE Kristensen","year":"2024","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the phase 3 keepsake 1 randomized clinical trial. Rheumatol Ther. 2024;11(3):617\u201332. https:\/\/doi.org\/10.1007\/s40744-024-00654-5.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"801_CR18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/rheumatology\/keac607","volume":"62","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2023;62(6):2113\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/keac607.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"801_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225\u201331. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221019.","journal-title":"Ann Rheum Dis"},{"key":"801_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S364640","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022. https:\/\/doi.org\/10.2147\/ccid.S364640.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"801_CR21","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372. https:\/\/doi.org\/10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"801_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the disease specific programme. BMJ Open. 2016;6(8):e010352. https:\/\/doi.org\/10.1136\/bmjopen-2015-010352.","journal-title":"BMJ Open"},{"key":"801_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380. https:\/\/doi.org\/10.2147\/DMSO.S120101.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"801_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy Jd, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on disease specific programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"801_CR25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3899\/jrheum.181089","volume":"46","author":"A Duarte-Garcia","year":"2019","unstructured":"Duarte-Garcia A, Leung YY, Coates LC, et al. Endorsement of the 66\/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report. J Rheumatol. 2019;46(8):996\u20131005. https:\/\/doi.org\/10.3899\/jrheum.181089.","journal-title":"J Rheumatol"},{"key":"801_CR26","unstructured":"European Pharmaceutical Market Research Association (EphMRA): Code of Conduct. https:\/\/www.ephmra.org\/code-conduct-aer (2022). Accessed 06 December 2022."},{"key":"801_CR27","unstructured":"US Department of Health and Human Services: Summary of the HIPAA Privacy Rule. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf (2003). Accessed 17 August 2022."},{"key":"801_CR28","unstructured":"Health Information Technology (HITECH): Health Information Technology Act. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf (2009). Accessed 17 August 2022."},{"issue":"3","key":"801_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A Ostor","year":"2022","unstructured":"Ostor A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221048.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"801_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/ijd.17156","volume":"63","author":"D Graceffa","year":"2024","unstructured":"Graceffa D, Zangrilli A, Caldarola G, et al. Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study. Int J Dermatol. 2024;63(10):1383\u201391. https:\/\/doi.org\/10.1111\/ijd.17156.","journal-title":"Int J Dermatol"},{"issue":"11","key":"801_CR31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/ijd.16849","volume":"62","author":"AG Vaiopoulos","year":"2023","unstructured":"Vaiopoulos AG, Dalamaga M, Katsimbri P, et al. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404\u201313. https:\/\/doi.org\/10.1111\/ijd.16849.","journal-title":"Int J Dermatol"},{"issue":"1","key":"801_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2133531","volume":"34","author":"CDB Elgaard","year":"2023","unstructured":"Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. 2023;34(1):2133531. https:\/\/doi.org\/10.1080\/09546634.2022.2133531.","journal-title":"J Dermatolog Treat"},{"key":"801_CR33","doi-asserted-by":"publisher","unstructured":"Walsh J, Wu J, Ye X, et al. Real-world switching patterns for patients with psoriatic arthritis on first-line advanced\u00a0therapies. Journal of Managed Care & Specialty Pharmacy. 2024;30(10-c):S108 - S9. https:\/\/doi.org\/10.18553\/jmcp.2024.30.10-c.s1.","DOI":"10.18553\/jmcp.2024.30.10-c.s1"},{"key":"801_CR34","doi-asserted-by":"publisher","unstructured":"Walsh J, Ye X, Peng Y, Patel M, Clewell J. Real-world dose escalation of biologic treatments for psoriatic arthritis. Journal of Managed Care & Specialty Pharmacy. 2024;30(10-c):S109. https:\/\/doi.org\/10.18553\/jmcp.2024.30.10-c.s1.","DOI":"10.18553\/jmcp.2024.30.10-c.s1"},{"issue":"10","key":"801_CR35","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3(10):e674\u201389. https:\/\/doi.org\/10.1016\/S2666-7568(22)00186-6.","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"801_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s13555-024-01174-4","volume":"14","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Khattri S, Amin AZ, et al. Enthesitis and dactylitis resolution with risankizumab for active psoriatic arthritis: integrated analysis of the randomized KEEPsAKE 1 and 2 trials. Dermatology and Therapy. 2024;14(6):1517\u201330. https:\/\/doi.org\/10.1007\/s13555-024-01174-4.","journal-title":"Dermatology and Therapy"},{"issue":"1","key":"801_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40744-018-0132-4","volume":"6","author":"LJ Tucker","year":"2019","unstructured":"Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019;6(1):23\u201332. https:\/\/doi.org\/10.1007\/s40744-018-0132-4.","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00801-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00801-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00801-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:46:53Z","timestamp":1763732813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00801-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00801-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jessica A Walsh has received consulting fees or research grants from AbbVie, Amgen, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB Pharma. Chistopher D Saffore, Xiaolan Ye, Manish Patel, Ana Biljan, and Jamie Vora are employees of AbbVie Inc. and may hold stock. Isabel Truman, Molly Edwards, and Gary Milligan are employees of Adelphi Real World. Andrew Ostor has received speaker or consulting fees and\/or research grants from AbbVie, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Using a checkbox, patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared with the subscriber and\/or for publication. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval. The survey materials were submitted to PEARL IRB (AG9361) and were deemed to be exempt (IRB ID 2023\u20130199). Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Helsinki Declaration of 1964 (and its later amendments), the US Health Insurance Portability and Accountability Act 1996, and Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}